BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BMS-986517 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BMS-986517\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07160725-11190@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:BMS-986517: Phase 1/2 readout est. (NCT07160725)
DESCRIPTION:BMS-986517\, phase 1/2\, Advanced Solid Tumors.\nStudy: A Phase
  1/2a\, First-in-human\, Study of BMS-986517 in Participants With Advanced
  Solid Tumors\nEstimated primary completion: 31 July 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bms-986517#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07160725
URL:https://assetmemo.bio/drug/bms-986517#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
